Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.

They could also offer a more potent option to conventional flu shots, according to mRNA vaccine developers. Current flu vaccines generally offer only around 40% to 60% protective efficacy ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

Messenger Ribonucleic Acid (mRNA) vaccines gained global recognition during the Coronavirus Disease 2019 (COVID-19) pandemic, proving their value through rapid development, high efficacy ...

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives. That same mRNA-powered approach to medicine—in which synthetic mRNA is ...

South Korean researchers have, for the first time in the world, uncovered how messenger ribonucleic acid (mRNA) vaccines enter human cells, function inside the body, and are blocked by certain ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.

In March, short sellers collectively increased their negative bets on the broader healthcare industry. Read more details here ...

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives. That same mRNA-powered approach to medicine—in which synthetic mRNA is ...